CalciMedica Inc. (NASDAQ:CALC) Sees Significant Growth in Short Interest

CalciMedica Inc. (NASDAQ:CALC – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 171,388 shares, a growth of 178.0% from the October 15th total of 61,641 shares. Currently, 3.5% of the company’s stock are short sold. Based on an average daily trading volume, of 96,501 shares, the days-to-cover ratio is presently 1.8 days.

Institutional Trading of CalciMedica

A hedge fund recently raised its position in CalciMedica stock. Renaissance Technologies LLC grew its position in shares of CalciMedica Inc. (NASDAQ:CALC – Free Report) by 45.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 128,075 shares of the company’s stock after buying an additional 39,775 shares during the quarter. Renaissance Technologies LLC owned 0.81% of CalciMedica worth $69,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

CalciMedica Stock Performance

Shares of CalciMedica stock traded down $0.01 during trading on Friday, hitting $1.21. 30,708 shares of the company’s stock traded hands, compared to its average volume of 81,136. CalciMedica has a 1 year low of $1.00 and a 1 year high of $36.00. The business has a 50-day simple moving average of $1.54 and a 200-day simple moving average of $3.00. The stock has a market capitalization of $8.34 million, a P/E ratio of -0.27 and a beta of 0.84. The company has a debt-to-equity ratio of 1.63, a current ratio of 4.96 and a quick ratio of 5.58.

CalciMedica (NASDAQ:CALC – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.03. As a group, analysts forecast that CalciMedica will post -1.93 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Guggenheim assumed coverage on CalciMedica in a report on Thursday, August 20th. They issued a “buy” rating on the stock. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Wall Street Zen downgraded shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. UBS Group restated a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $50.00.

View Our Latest Stock Report on CALC

About CalciMedica

(Get Free Report)

CalciMedica is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation. The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development.

See Also

Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.